ReviewCureus2026
Subarachnoid Hemorrhage Causing Hydrocephalus: Narrative Review of a Neurosurgical Emergency.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrocephalus is a common complication following aneurysmal subarachnoid hemorrhage (aSAH) and remains one of the most frequent causes of readmission in patients with subarachnoid hemorrhage (SAH). If left untreated, hydrocephalus may lead to significant neurological deterioration and can be fatal; therefore, it represents a neurosurgical emergency. This review summarizes the current understanding of hydrocephalus following SAH based on the available literature. Hydrocephalus occurs in approximately one third (1/3) of patients with SAH. Depending on the timing of onset, it can be classified as acute, subacute, or chronic hydrocephalus. The underlying pathophysiology is multifactorial and includes obstruction of cerebrospinal fluid (CSF) circulation by blood clots and blood degradation products, impaired CSF absorption due to inflammation and fibrosis, and in some cases increased CSF production. Diagnosis is primarily based on clinical deterioration and neuroimaging findings, with computed tomography (CT) of the brain remaining the gold standard for detecting ventricular enlargement and confirming the presence of hydrocephalus. Management of acute hydrocephalus mainly involves CSF diversion, most commonly through external ventricular drainage (EVD). In some patients, hydrocephalus may persist and progress to a chronic form requiring permanent CSF diversion with ventriculoperitoneal (VP) or lumboperitoneal (LP) shunts. Hydrocephalus following SAH is associated with increased mortality, prolonged hospitalization, and long-term neurological impairment, emphasizing the importance of early diagnosis and timely management to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.